CIK 0001637715 · <br>Emerging growth company
OnKure Therapeutics, Inc.
Sign in to watch- Ticker
- OKUR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 472309515
- Phone
- (720) 307-2892
- Business address
- 6707 WINCHESTER CIRCLE, SUITE 400, BOULDER, CO, 80301
- Former names
- Reneo Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,157
- in 2 filings
Net −$1,157. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-09-21 | Leverone Jason A. Chief Financial Officer | Sale | −302 | $2.97 | $898 | 18,500 |
| 2026-09-21 | Saccomano Nicholas A President and CEO | Sale | −87 | $2.97 | $259 | 11,160 |
| 2026-08-07 | Hartley Dylan Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2026-08-07 | Hartley Dylan Chief Scientific Officer | Returned to the company · Employee Stock Option (right to buy) | −137,603 | 0 | ||
| 2026-08-07 | Hartley Dylan Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +137,603 | 137,603 | ||
| 2026-08-07 | Phillips Andrew John Director | Grant or award · Stock Option (right to buy) | +22,350 | 22,350 | ||
| 2026-08-07 | Jansen Valerie Malyvanh Director | Grant or award · Stock Option (right to buy) | +22,350 | 22,350 | ||
| 2026-08-07 | Agresta Samuel Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2026-08-07 | Agresta Samuel Chief Medical Officer | Returned to the company · Employee Stock Option (right to buy) | −18,588 | 0 | ||
| 2026-08-07 | Agresta Samuel Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +18,588 | 18,588 | ||
| 2026-08-07 | Agresta Samuel Chief Medical Officer | Returned to the company · Employee Stock Option (right to buy) | −131,396 | 0 | ||
| 2026-08-07 | Agresta Samuel Chief Medical Officer | Grant or award · Employee Stock Option (right to buy) | +131,396 | 131,396 | ||
| 2026-08-07 | Leverone Jason A. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2026-08-07 | Leverone Jason A. Chief Financial Officer | Returned to the company · Employee Stock Option (right to buy | −5,781 | 0 | ||
| 2026-08-07 | Leverone Jason A. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy | +5,781 | 5,781 | ||
| 2026-08-07 | Leverone Jason A. Chief Financial Officer | Returned to the company · Employee Stock Option (right to buy) | −5,322 | 0 | ||
| 2026-08-07 | Leverone Jason A. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +5,322 | 5,322 | ||
| 2026-08-07 | Leverone Jason A. Chief Financial Officer | Returned to the company · Employee Stock Option (right to buy) | −130,611 | 0 | ||
| 2026-08-07 | Leverone Jason A. Chief Financial Officer | Grant or award · Employee Stock Option (right to buy) | +130,611 | 130,611 | ||
| 2026-08-07 | Carruthers R Michael Director | Grant or award · Stock Option (right to buy) | +22,350 | 22,350 |
Page 1 of 8 · 154 trades